CN119072492A - 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 - Google Patents

抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 Download PDF

Info

Publication number
CN119072492A
CN119072492A CN202380036069.7A CN202380036069A CN119072492A CN 119072492 A CN119072492 A CN 119072492A CN 202380036069 A CN202380036069 A CN 202380036069A CN 119072492 A CN119072492 A CN 119072492A
Authority
CN
China
Prior art keywords
adm
adrenomedullin
antibody
pharmaceutical formulation
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380036069.7A
Other languages
English (en)
Chinese (zh)
Inventor
贾里德·戈尔德斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adrenomed AG
Original Assignee
Adrenomed AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adrenomed AG filed Critical Adrenomed AG
Publication of CN119072492A publication Critical patent/CN119072492A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202380036069.7A 2022-03-15 2023-03-15 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂 Pending CN119072492A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22162271 2022-03-15
EP22162271.5 2022-03-15
PCT/EP2023/056663 WO2023175035A1 (en) 2022-03-15 2023-03-15 Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment

Publications (1)

Publication Number Publication Date
CN119072492A true CN119072492A (zh) 2024-12-03

Family

ID=80780591

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380036069.7A Pending CN119072492A (zh) 2022-03-15 2023-03-15 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂

Country Status (9)

Country Link
US (1) US20250304671A1 (enExample)
EP (1) EP4493588A1 (enExample)
JP (1) JP2025509304A (enExample)
CN (1) CN119072492A (enExample)
AU (1) AU2023233838A1 (enExample)
CA (1) CA3254142A1 (enExample)
IL (1) IL315632A (enExample)
MX (1) MX2024010899A (enExample)
WO (1) WO2023175035A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025056807A1 (en) * 2023-09-15 2025-03-20 Basf Se Stabilized biopolymer composition, their manufacture and use
WO2025133235A1 (en) * 2023-12-22 2025-06-26 Pam Theragnostics Gmbh Adm-gly as marker for early predicting sepsis
WO2026046978A1 (en) * 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2002213441B2 (en) * 2000-10-12 2006-10-26 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2002323501C1 (en) 2001-08-30 2010-04-29 Biorexis Technology, Inc Modified transferrin fusion proteins
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
US20050164301A1 (en) 2003-10-24 2005-07-28 Avidia Research Institute LDL receptor class A and EGF domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
AU2005287557B2 (en) 2004-09-21 2011-10-13 Biontech Ag Use of microproteins as tryptase inhibitors
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
RU2553333C2 (ru) 2009-12-14 2015-06-10 Сцил Протеинс Гмбх Способ идентификации гетеромультимерных модифицированных убиквитиновых белков со способностью связываться с лигандами
PL2580236T3 (pl) 2010-06-08 2019-09-30 Pieris Pharmaceuticals Gmbh Muteiny lipokaliny łez wiążące IL-4 R alfa
ES2494190T3 (es) 2011-11-16 2014-09-15 Adrenomed Ag Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
IL283215B2 (en) 2011-11-16 2024-05-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
LT3553084T (lt) 2011-11-16 2023-03-10 Adrenomed Ag Anti-adrenomedulino (adm) antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne-ig karkasas, skirtas organų funkcijos sutrikimo arba organų nepakankamumo profilaktikai arba sumažinimui paciento, sergančio lėtine arba ūmine liga arba esančio ūminės būklės, organizme
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
PT2780371T (pt) 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
DE112017002105T5 (de) 2016-04-21 2019-04-25 Sphingotec Therapeutics Gmbh Verfahren zur Bestimmung von DPP3 und therapeutische Verfahren
JP7727371B2 (ja) 2016-12-16 2025-08-21 アドレノメト アクチェンゲゼルシャフト うっ血の処置と治療を必要とする患者でその処置と治療に使用するための抗アドレノメデュリン（ＡＤＭ）抗体、または抗ＡＤＭ抗体フラグメント、または抗ＡＤＭ非Ｉｇ足場
WO2019077082A1 (en) * 2017-10-18 2019-04-25 Adrenomed Ag SURVEILLANCE OF THERAPY UNDER TREATMENT WITH ANTI-ADRENOMEDULIN BINDER (ADM)
CN115244080A (zh) * 2020-02-27 2022-10-25 艾德里诺医药公司 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架

Also Published As

Publication number Publication date
IL315632A (en) 2024-11-01
CA3254142A1 (en) 2023-09-21
AU2023233838A1 (en) 2024-09-26
JP2025509304A (ja) 2025-04-11
MX2024010899A (es) 2024-12-06
WO2023175035A1 (en) 2023-09-21
EP4493588A1 (en) 2025-01-22
US20250304671A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
CN119072492A (zh) 抗肾上腺髓质素（adm）抗体或抗adm抗体片段的稳定水性制剂
JP6224608B2 (ja) 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場
CN111511390B (zh) 用于治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
US20240279323A1 (en) Methods for the treatment of scleroderma and related conditions
US12077578B2 (en) Compositions and methods for treating synucleinopathies
US20240158516A1 (en) Methods for the treatment of thyroid eye disease
JP6321667B2 (ja) 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥｓ）のための配合物
WO2022017468A1 (zh) Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途
JP2023507795A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
WO2021052472A1 (zh) 抗pcsk9抗体用于预防或治疗胆固醇相关疾病的方法
US20260022197A1 (en) Methods of reversing ticagrelor activity
RU2790561C2 (ru) Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания
EP4023218A1 (en) Combination therapy for patients having acute and/or persistent dyspnea
HK40120349A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40083955A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40085254A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
HK40120923A (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂
AU2024343373A1 (en) Antibody formulation
HK40058594A (en) Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
CN116077650A (zh) 一种稳定的新冠中和抗体的药物组合物及其应用
WO2026092660A1 (zh) 抗her2抗体药物偶联物和抗pd-l1抗体联合在制备治疗乳腺癌的药物中的用途
WO2021207667A1 (en) Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
JP2023515985A (ja) ショック状態の患者の治療において使用するための抗アドレノメデュリン（ａｄｍ）結合剤
HK40032645B (zh) 用於治疗或预防疾病症状的抗肾上腺髓质素(adm)结合剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination